"Als größtes Universitätsklinikum im Norden deckt das UKSH mit 92 Kliniken und Instituten in Kiel und Lübeck das gesamte Spektrum der modernen Medizin ab. 500.000 Patientinnen und Patienten profitieren jedes Jahr von der engen Verknüpfung der Spitzenmedizin des UKSH mit der innovativen Forschung der Universitäten in Kiel und Lübeck. Forschungsergebnisse gelangen hier direkt in die medizinische Praxis. Das Ergebnis ist ein exzellentes klinisches Niveau: Das UKSH ist Garant für höchst individualisierte sowie interdisziplinäre Diagnostik und Therapie. Dazu zählen medizinische Innovationen wie die Präzisionsmedizin für chronische Entzündungserkrankungen und Krebserkrankungen ebenso wie die digitalen Medien."

During the past decade, UKSH Campus Lübeck conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 5 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UKSH Campus Lübeck" #1 sponsor was "Biotronik SE & Co. KG" with 2 trials, followed by "C. R. Bard" with 1 trials sponsored, "Cerus Endovascular, Ltd" with 1 trials sponsored, "LEO Pharma" with 1 trials sponsored and "Medtronic Cardiovascular" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UKSH Campus Lübeck" #1 collaborator was "Biotronik, Inc." with 1 trials as a collaborator, "Deutsche Kinderkrebsstiftung" with 1 trials as a collaborator and "Hannover Medical School" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "UKSH Campus Lübeck" are "Heart Failure" (2 trials), "Anaplastic Astrocytoma WHO Grade III" (1 trials), "Aneurysm, Brain" (1 trials), "Covid-19" (1 trials) and "Diffuse Intrinsic Pontine Glioma" (1 trials). Many other conditions were trialed in "UKSH Campus Lübeck" in a lesser frequency.

Most popular intervention types in "UKSH Campus Lübeck" are "Device" (6 trials) and "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "ATS 3f Enable Aortic Bioprosthesis Model 6000" (1 trials), "Contour Neurovascular System" (1 trials), "Double Placebo Control" (1 trials), "LEO 90100 aerosol foam" (1 trials) and "LEO 90100 aerosol foam vehicle" (1 trials). Other intervention names were less common.

The vast majority of trials in "UKSH Campus Lübeck" are 11 trials for "All" genders.

Currently, there are NaN active trials in "UKSH Campus Lübeck". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in UKSH Campus Lübeck, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in UKSH Campus Lübeck, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".